Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation–associated metastatic renal-cell carcinoma

Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR) pathway, is currently approved for treatment of advanced renal-cell carcinoma (RCC) after failure of initial treatment with the tyrosine kinase inhibitors. Patients with tuberous sclerosis complex (TSC) syndrome can also devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsidawi, Samer, Kasi, Pashtoon Murtaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880255/
https://www.ncbi.nlm.nih.gov/pubmed/29610387
http://dx.doi.org/10.1101/mcs.a002220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880255/
https://www.ncbi.nlm.nih.gov/pubmed/29610387
http://dx.doi.org/10.1101/mcs.a002220

Ejemplares similares